1. Home
  2. BUI vs REPL Comparison

BUI vs REPL Comparison

Compare BUI & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Utility Infrastructure & Power Opportunities Trust

BUI

BlackRock Utility Infrastructure & Power Opportunities Trust

HOLD

Current Price

$30.50

Market Cap

601.7M

Sector

Finance

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$7.69

Market Cap

692.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BUI
REPL
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
601.7M
692.8M
IPO Year
2011
2018

Fundamental Metrics

Financial Performance
Metric
BUI
REPL
Price
$30.50
$7.69
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$11.13
AVG Volume (30 Days)
64.1K
1.1M
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.25
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.27
$2.68
52 Week High
$30.43
$13.24

Technical Indicators

Market Signals
Indicator
BUI
REPL
Relative Strength Index (RSI) 88.07 45.88
Support Level $25.57 $6.90
Resistance Level N/A $8.07
Average True Range (ATR) 0.39 0.55
MACD 0.11 0.04
Stochastic Oscillator 97.32 28.44

Price Performance

Historical Comparison
BUI
REPL

About BUI BlackRock Utility Infrastructure & Power Opportunities Trust

BlackRock Utility Infrastructure & Power Opportunities Trust is a closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing of writing (selling) call and put options.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: